fig3

Figure 3. Effects of PD-0332991 on two primary PDAC cell lines in vitro. (A) Time- and dose-dependent effects of PD-0332991 on 70301 (upper) and 60400 (lower) cells; (B and C) EdU assay showing cell viability after treatment with PD-0332991 (1 μM), with or without JQ1 (500 nM). Scales bars,100 μm; (D) Wound healing assays showing enhanced migration following 100 and 500 nM PD-0332991 treatment for 24 h. Scales bars, 100 μm; (E) Quantification of wound healing assays for 70301 and 60400 cells; (F) Transwell invasion assays demonstrating effects of PD-0332991 and JQ1. Scales bars, 200 μm. Data are mean ± SEM from three independent experiments or three randomly selected fields per experiment. ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, ^****P < 0.0001; ns: not significant. PDAC: Pancreatic ductal adenocarcinoma; EdU: 5-ethynyl-2′-deoxyuridine; SEM: standard error of the mean.